Adjuvant and neoadjuvant imatinib therap
β
Burton L. Eisenberg; Jonathan C. Trent
π
Article
π
2011
π
John Wiley and Sons
π
French
β 212 KB
## Abstract Although surgery remains the mainstay for the treatment of primary gastrointestinal stromal tumors (GIST), a significant number of patients experience disease recurrence within 5 years of surgery. The emergence of imatinib therapy for the treatment of patients with advanced GIST has off